Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis

Browning, Jeffrey D.; Kumar, K. Shiva; Saboorian, M. Hossein; Thiele, Dwain L.
February 2004
American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p292
Academic Journal
OBJECTIVES: Nonalcoholic steatohepatitis (NASH) associated with obesity and type 2 diabetes mellitus (DM) is postulated to be the cause of most cases of cryptogenic cirrhosis (CC). While ethnic differences in the prevalence of obesity and DM in the United States are well documented, there is little information regarding prevalence of CC or NASH among different U.S. ethnic groups. This study was performed to assess the demographic characteristics of patients with CC at a U.S. county hospital with a racially and ethnically diverse patient population.METHODS: Medical records and pathology databases were reviewed to identify patients at Parkland Memorial Hospital, Dallas County, Texas from 1990 to 2001 with CC or cirrhosis attributed to NASH.RESULTS: Forty-one patients (12 men, 29 women) were found to meet these criteria. Of these, 68% were obese (BMI≥ 30) and/or had type 2 DM and 74% of liver biopsies revealed one or more features of NASH. Of patients with CC 68% were Hispanic while only 7% were African American, despite the fact that Hispanics comprised<26% and African Americans>40% of adult medicine patients. Prevalence of CC among Hispanic and African American patients was 3.1-fold higher and 3.9-fold lower, respectively, than among European American patients despite similar prevalence of DM among Hispanics and African Americans.CONCLUSION: These findings support the hypothesis that NASH associated with obesity and DM is responsible for the majority of cases of CC among Hispanics and European Americans. However, the current findings also indicate that this form of cirrhosis is unexpectedly rare among African Americans.


Related Articles

  • Hepatic steatosis and type 2 diabetes mellitus. Salas-Flores, Ricardo; González-Pérez, Brian; Echegollen-Guzmán, Alonso // Revista Medica del IMSS;2012, Vol. 50 Issue 1, p13 

    Background: patients with type 2 diabetes mellitus (T2DM) appear to have an increased risk of developing nonalcoholic fatty liver disease (NAFLD) and have higher risk to develop hepatic fibrosis and cirrhosis. The aim was to determine the prevalence of NAFLD in health workers with T2DM by liver...

  • Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Morita, Shinhiti; Neto, Dalísio; Morita, Flávio; Morita, Nina; Lobo, Suzana // Obesity Surgery;Dec2015, Vol. 25 Issue 12, p2335 

    Background: Non-alcoholic fatty liver disease (NAFLD) associated with obesity comprises pathological changes ranging from steatosis to steatohepatitis; these can evolve to cirrhosis and hepatocellular carcinoma. Objectives: The objectives of this study are to assess the prevalence of and...

  • 73-Year-Old Man With Increasing Abdominal Girth and Dyspnea. REPPERT, SARA L.; WITTICH, CHRISTOPHER M. // Mayo Clinic Proceedings;Oct2011, Vol. 86 Issue 10, p1002 

    The article reports on nonalcoholic fatty liver disease (NAFLD), which begins with steatosis and ends with cirrhosis. It states the histologic changes in NAFLD are similar to those in alcoholic liver disease, but occurs in patients who report drinking little alcohol. It states diabetes, obesity...

  • Is NASH underdiagnosed among African Americans? Caldwell, Stephen H.; Harris, Danielle M.; Patrie, James T.; Hespenheide, Elizabeth E. // American Journal of Gastroenterology;Jun2002, Vol. 97 Issue 6, p1496 

    OBJECTIVE:Obesity and type 2 diabetes mellitus are considered risk factors for nonalcoholic steatohepatitis (NASH) and cryptogenic cirrhosis. Because obesity and type 2 diabetes are prevalent among African American females by the 5th and 6th decades, one would expect an increased number of...

  • Liver disease: Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?: Non-alcoholic fatty liver disease. Fisher, Roy // Annals of Clinical Biochemistry;Nov2002, Vol. 39 Issue 6, p624 

    The article reports on the two studies regarding the importance of non-alcoholic fatty liver disease (NAFLD) as another disease of affluence that affects 10-24 percent of the general population in Great Britain. It states that NAFLD is potentially progressive, covering the spectrum from simple...

  • Other aspects of bariatric surgery: liver steatosis, ferritin and cholesterol metabolism. Pontiroli, A. E. // Nutricion Hospitalaria;mar/abr suplemento 2, Vol. 28, p104 

    Bariatric surgery developed in the late 1970 to treat severe hyperlipidemias in overweight individuals, not necessarily obese. Several techniques have been developed, and the concept has come first of a surgery for morbid obesity, then of a cure for diabetes in morbid obesity. There are other...

  • Long-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy. Javor, Edward D.; Cochran, Elaine K.; Musso, Carla; Young, Janice Ryan; DePaoli, Alex M.; Gorden, Phillip // Diabetes;Jul2005, Vol. 54 Issue 7, p1994 

    Ectopic fat accumulation has been implicated as a contributing factor in the abnormal metabolic state of obesity. One human model of ectopic fat deposition is generalized lipodystrophy. Generalized lipodystrophy is a rare disorder characterized by a profound deficiency of adipose tissue with...

  • In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD). Kanuri, Giridhar; Bergheim, Ina // International Journal of Molecular Sciences;Jun2013, Vol. 14 Issue 6, p11963 

    By now, non-alcoholic fatty liver disease (NAFLD) is considered to be among the most common liver diseases world-wide. NAFLD encompasses a broad spectrum of pathological conditions ranging from simple steatosis to steatohepatitis, fibrosis and finally even cirrhosis; however, only a minority of...

  • Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Klein, Thomas; Fujii, Masato; Sandel, Jan; Shibazaki, Yuichiro; Wakamatsu, Kyoko; Mark, Michael; Yoneyama, Hiroyuki // Medical Molecular Morphology;Sep2014, Vol. 47 Issue 3, p137 

    Non-alcoholic steatohepatitis (NASH) is a primary cause of cirrhosis and hepatocellular carcinoma. Dipeptidyl peptidase (DPP)-4 inhibitors are established therapies for type 2 diabetes and although DPP-4 inhibitors can reduce hepatic steatosis, their impact on local inflammation and fibrosis in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics